Analyst Rating Update on Vascular Biogenics Ltd. (VBLT)

Vascular Biogenics Ltd. (NASDAQ:VBLT) : The consensus on Vascular Biogenics Ltd. (NASDAQ:VBLT) based on 4 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.

Vascular Biogenics Ltd. (NASDAQ:VBLT) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $22 and the lowest price target forecast is $14. The average forecast of all the analysts is $18 and the expected standard deviation is $3.65.

For the current week, the company shares have a recommendation consensus of Buy.

Vascular Biogenics Ltd. (NASDAQ:VBLT): stock turned positive on Tuesday. Though the stock opened at $4.35, the bulls momentum made the stock top out at $4.67 level for the day. The stock recorded a low of $4.05 and closed the trading day at $4.1, in the green by 3.80%. The total traded volume for the day was 1,289,892. The stock had closed at $3.95 in the previous days trading.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Companys program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. The Company is developing VB-111, the lead oncology product candidate from its VTS platform technology, which is a gene-based biologic for the treatment of solid tumor indications, with clinical programs in recurrent glioblastoma (rGBM), thyroid cancer and ovarian cancer. The Company is also conducting a program targeting anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules developed by the Company that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.